482 related articles for article (PubMed ID: 33153401)
1. Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis.
Mokadem ME; Hassan A; Algaby AZ
Vascular; 2021 Oct; 29(5):745-750. PubMed ID: 33153401
[TBL] [Abstract][Full Text] [Related]
2. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
[TBL] [Abstract][Full Text] [Related]
3. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
[TBL] [Abstract][Full Text] [Related]
4. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
[TBL] [Abstract][Full Text] [Related]
6. Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
Houghton DE; Vlazny DT; Casanegra AI; Brunton N; Froehling DA; Meverden RA; Hodge DO; Peterson LG; McBane RD; Wysokinski WE
Mayo Clin Proc; 2021 Nov; 96(11):2793-2805. PubMed ID: 34425962
[TBL] [Abstract][Full Text] [Related]
7. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
; Buller H; Deitchman D; Prins M; Segers A
J Thromb Haemost; 2008 Aug; 6(8):1313-8. PubMed ID: 18541000
[TBL] [Abstract][Full Text] [Related]
9. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
Weitz JI; Segers A; Raskob G; Roberts RS; Francis C; Lassen MR; Fuji T; Swaim RM; Lee M; Peters G; DiBattiste PM; Tesfaye F; Strony J
J Thromb Haemost; 2019 Dec; 17(12):2081-2088. PubMed ID: 31529590
[TBL] [Abstract][Full Text] [Related]
11. Oral apixaban for the treatment of acute venous thromboembolism.
Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
[TBL] [Abstract][Full Text] [Related]
12. Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside.
Poredos P; Jezovnik MK
Curr Drug Targets; 2018; 19(6):577-580. PubMed ID: 25981607
[TBL] [Abstract][Full Text] [Related]
13. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
[TBL] [Abstract][Full Text] [Related]
14. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Stepien K; Nowak K; Zalewski J; Pac A; Undas A
Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
[TBL] [Abstract][Full Text] [Related]
15. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
16. Apixaban. After hip or knee replacement: LMWH remains the standard treatment.
Prescrire Int; 2012 Sep; 21(130):201-2, 204. PubMed ID: 23016247
[TBL] [Abstract][Full Text] [Related]
17. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial.
McBane RD; Loprinzi CL; Zemla T; Tafur A; Sanfilippo K; Liu JJ; Garcia DA; Heun J; Gundabolu K; Onitilo AA; Perepu U; Drescher MR; Henkin S; Houghton D; Ashrani A; Billett H; McCue SA; Lee MK; Le-Rademacher JG; Wysokinski WE;
J Thromb Haemost; 2024 Jun; 22(6):1704-1714. PubMed ID: 38537780
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center.
Knisely A; Iniesta MD; Batman S; Meyer LA; Soliman PT; Cain KE; Marten C; Chisholm G; Schmeler KM; Taylor JS; Fleming ND
Gynecol Oncol; 2024 Apr; 183():120-125. PubMed ID: 38368180
[TBL] [Abstract][Full Text] [Related]
19. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban.
Houghton DE; Casanegra AI; Peterson LG; Cochuyt J; Hodge DO; Vlazny D; McBane RD; Froehling D; Wysokinski WE
Am J Hematol; 2020 Jul; 95(7):817-823. PubMed ID: 32267011
[TBL] [Abstract][Full Text] [Related]
20. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
